Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPSC1001 (VSVΔG-ZEBOV) in Healthy Adults in Kenya
NCT02296983Phase 1Unknown
- Sponsor
- University of Oxford
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 cohorts), sponsored by University of Oxford. Primary endpoint: Nature, frequency, and severity of adverse events and/or serious adverse events. Status: unknown.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02296983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296983.